<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02387710</url>
  </required_header>
  <id_info>
    <org_study_id>BWH-2012P000956B</org_study_id>
    <nct_id>NCT02387710</nct_id>
  </id_info>
  <brief_title>Tiagabine to Enhance Slow Wave Sleep in Patients With Sleep Apnea</brief_title>
  <acronym>TESSA</acronym>
  <official_title>Inducing Slow Wave Sleep to Treat Obstructive Sleep Apnea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Obstructive sleep apnea (OSA) is common and has major health implications but treatment
      options are limited. Interestingly, the severity of OSA is profoundly reduced in deep sleep
      (called &quot;slow wave sleep&quot;), potentially via an increase in the stimulus required to arouse
      from sleep. Here the investigators test the idea that the medication called &quot;tiagabine&quot;
      improves slow wave sleep and reduces OSA severity. The investigators will also test whether
      tiagabine raises the arousal threshold (more negative esophageal pressure), and whether
      detailed OSA &quot;phenotyping&quot; characteristics can predict the improvement in OSA severity with
      this intervention.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The current study tests the primary hypothesis that tiagabine improves sleep apnea severity
      in patients with moderate-to-severe sleep apnea (apnea hypopnea index measured in supine
      non-REM sleep; hypopneas defined by 3% desaturation or arousal). The investigators test three
      secondary hypotheses that tiagabine:

        1. increases the proportion of total sleep time in slow wave sleep

        2. raises the non-REM arousal threshold (more negative esophageal pressure) via (1).

        3. is preferentially effective in patients whose OSA phenotype predicts that an increase in
           the arousal threshold is sufficient to resolve OSA versus those without such favorable
           physiology. Favorable physiology is defined here as having a low ventilatory drive at
           which stable breathing is theoretically feasible (&quot;stable Vdrive&quot; is &lt;100% above eupneic
           ventilatory drive) due to any combination of a &quot;high&quot; upper airway muscle response,
           &quot;good&quot; passive anatomy (high Vpassive), and &quot;low&quot; steady-state loop gain (see Owens RL
           et al SLEEP 2014; Wellman A et al J Appl Physiol 2011, 2013; Eckert DJ et al 2013
           AJRCCM).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Apnea Hypopnea Index (AHI)</measure>
    <time_frame>1 night</time_frame>
    <description>Number of apneas + hypopneas per hour of sleep. Hypopnea criteria: reduction in 30% of baseline flow plus 3% desaturation or arousal.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Slow Wave Sleep (% Total Sleep Time)</measure>
    <time_frame>1 night</time_frame>
    <description>Fraction of sleep spent in stage N3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arousal Threshold (Esophageal Pressure Swing)</measure>
    <time_frame>1 night</time_frame>
    <description>The arousal threshold was quantified as the mean of all the nadir negative esophageal pressure swings immediately preceding an arousal at the end of an obstructive apnea or hypopnea during both placebo and tiagabine nights.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Sleep Apnea, Obstructive</condition>
  <arm_group>
    <arm_group_label>Tiagabine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tiagabine PO 12 mg before sleep</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo PO before sleep</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiagabine</intervention_name>
    <description>GABA reuptake inhibitor</description>
    <arm_group_label>Tiagabine</arm_group_label>
    <other_name>Gabitril</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo comparator</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed OSA (moderate-to-severe; apnea hypopnea index &gt;15 events/hr)

        Exclusion Criteria:

          -  History of seizures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Sleep Disorders Research Program Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 9, 2015</study_first_submitted>
  <study_first_submitted_qc>March 12, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 13, 2015</study_first_posted>
  <results_first_submitted>May 16, 2017</results_first_submitted>
  <results_first_submitted_qc>May 16, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">June 6, 2017</results_first_posted>
  <last_update_submitted>July 14, 2017</last_update_submitted>
  <last_update_submitted_qc>July 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>David Andrew Wellman</investigator_full_name>
    <investigator_title>Director, Sleep Disordered Breathing Laboratory</investigator_title>
  </responsible_party>
  <keyword>arousal threshold</keyword>
  <keyword>phenotype</keyword>
  <keyword>tiagabine</keyword>
  <keyword>slow wave sleep</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tiagabine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Tiagabine First, Placebo Second</title>
          <description>Tiagabine 12 mg administered at normal sleep time on first study night, then a 1-week non-treatment period, then placebo-matching tiagabine administered at normal sleep time on second study night.</description>
        </group>
        <group group_id="P2">
          <title>Placebo First, Tiagabine Second</title>
          <description>Placebo-matching tiagabine administered at normal sleep timeon first study night, then a 1-week non-treatment, then tiagabine 12 mg administered at normal sleep time on second study night</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Study Night</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second Study Night</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="7">2 patients did not come back for excessive sleep disruption due to the equipment</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>18 patients enrolled, 2 did not completed the study, One patient was excluded because of predominantly central sleep apnea on both nights, and another was excluded because of low-quality EEG data. Therefore, 14 subjects were analyzed.</population>
      <group_list>
        <group group_id="B1">
          <title>All Analyzed Participants</title>
          <description>All patients who were randomized, completed both study nights and were included in the analysis</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58" lower_limit="51" upper_limit="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Apnea Hypopnea Index (AHI)</title>
        <description>Number of apneas + hypopneas per hour of sleep. Hypopnea criteria: reduction in 30% of baseline flow plus 3% desaturation or arousal.</description>
        <time_frame>1 night</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tiagabine</title>
            <description>Tiagabine 12 mg administered at sleep time on the first or second study night</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo administered at sleep time on the first or second study night</description>
          </group>
        </group_list>
        <measure>
          <title>Apnea Hypopnea Index (AHI)</title>
          <description>Number of apneas + hypopneas per hour of sleep. Hypopnea criteria: reduction in 30% of baseline flow plus 3% desaturation or arousal.</description>
          <units>events/hour</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.1" lower_limit="32.1" upper_limit="48.7"/>
                    <measurement group_id="O2" value="40.8" lower_limit="31.4" upper_limit="51.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&gt;0.5</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Slow Wave Sleep (% Total Sleep Time)</title>
        <description>Fraction of sleep spent in stage N3</description>
        <time_frame>1 night</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tiagabine</title>
            <description>Tiagabine 12 mg administered at sleep time on the first or second study night</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo administered at sleep time on the first or second study night</description>
          </group>
        </group_list>
        <measure>
          <title>Slow Wave Sleep (% Total Sleep Time)</title>
          <description>Fraction of sleep spent in stage N3</description>
          <units>% total sleep time</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.3" lower_limit="4.52" upper_limit="20.6"/>
                    <measurement group_id="O2" value="8.8" lower_limit="5.2" upper_limit="15.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Arousal Threshold (Esophageal Pressure Swing)</title>
        <description>The arousal threshold was quantified as the mean of all the nadir negative esophageal pressure swings immediately preceding an arousal at the end of an obstructive apnea or hypopnea during both placebo and tiagabine nights.</description>
        <time_frame>1 night</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tiagabine</title>
            <description>Tiagabine 12 mg administered at sleep time on the first or the second study night</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo administered at sleep time on the first or the second study night</description>
          </group>
        </group_list>
        <measure>
          <title>Arousal Threshold (Esophageal Pressure Swing)</title>
          <description>The arousal threshold was quantified as the mean of all the nadir negative esophageal pressure swings immediately preceding an arousal at the end of an obstructive apnea or hypopnea during both placebo and tiagabine nights.</description>
          <units>cmH2O</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.6" lower_limit="-28.6" upper_limit="-23.6"/>
                    <measurement group_id="O2" value="-26.5" lower_limit="-27.9" upper_limit="-23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Tiagabine</title>
          <description>Tiagabine 12 mg administered at sleep time on the first or second study night</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo administered at sleep time on the first or second study night</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Andrew Wellman, MD, PhD</name_or_title>
      <organization>Brigham and women's Hospital</organization>
      <email>awellman@rics.bwh.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

